Similar articles

• Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.

  [No authors listed] [No authors listed] Technol Eval Cent Assess Program Exec Summ. 2011 Mar;25(6):1-5. Technol Eval Cent Assess Program Exec Summ. 2011. PMID: 21638942 No abstract available.
• Gefitinib Approved for EGFR-Mutated NSCLC.

  [No authors listed] [No authors listed] Cancer Discov. 2015 Sep;5(9):896. doi: 10.1158/2159-8290.CD-NB2015-111. Epub 2015 Aug 3. Cancer Discov. 2015. PMID: 26238462 No abstract available.
• EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.

  Shih JY, Gow CH, Yang PC. Shih JY, et al. N Engl J Med. 2005 Jul 14;353(2):207-8. doi: 10.1056/NEJM200507143530217. N Engl J Med. 2005. PMID: 16014893 No abstract available.
• Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.

  Santarpia M, Altavilla G, Salazar MF, Magri I, Pettineo G, Benecchi S, Rosell R. Santarpia M, et al. Expert Rev Respir Med. 2011 Jun;5(3):413-24. doi: 10.1586/ers.11.27. Expert Rev Respir Med. 2011. PMID: 21702662 Review.
• Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.

  Amler LC, Goddard AD, Hillan KJ. Amler LC, et al. Cold Spring Harb Symp Quant Biol. 2005;70:483-8. doi: 10.1101/sqb.2005.70.048. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869787 Review.